CAR-NK疗法在急性髓系白血病中的应用研究进展OA

Chimeric antigen receptor(CAR)T-cell therapy for B-cell hematologic malignancies has achieved breakthrough success;however,its efficacy for acute myeloid leukemia(AML)is constrained by the lack of highly specific tumor antigens and the expression of shared targets on normal hematopoietic stem/progenitor cells,increasing the risk of on-target myelosuppression and cytokine release syndrome(CRS).By contrast,CAR-NK cell therapy,an emerging strategy that leverages the innate antitumor activity of natural killer cells,is associated with low rates of CRS and graft-versus-host disease.Early clinical studies also indicate its favorable safety profile with preliminary antileukemic activity.This review summarizes recent advances in CAR-NK therapy for AML and discusses future directions and potential avenues for clinical translation.